GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 23, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
Related Tickers: C
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on April 23, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- 001-15170 (dollar_amount) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transaction in its own shares.
Who is acting as GSK's stockbroker for this transaction?
Citigroup Global Markets Limited is acting as GSK's corporate stockbroker.
On what date was this transaction announced?
The transaction was announced on April 23, 2025.
Does the filing specify the number of shares purchased?
No, the filing states that GSK has purchased 'the following number of the Company's ordinary shares' but does not provide the specific quantity in the provided text.
What is the par value of GSK's ordinary shares?
The ordinary shares have a par value of 31 1/4 pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2025 regarding GSK plc (GLAXF).